Drug interactions of clinical importance with methadone and buprenorphine.
Drug interactions of clinical importance with methadone and buprenorphine.
复制标题
与美沙酮和丁丙诺啡具有临床重要性的药物相互作用。
DOI：
10.1111/j.1521-0391.2009.00011.x
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Mandell,ToddW
中科院分区：
文献类型：
--
作者：
McCance-Katz,ElinoreF;Mandell,ToddW
药物相互作用是美国发病率和死亡率的重要来源。医学研究所在2000年报告说，估计每年有多达44，000至98，000人死于医疗差错。1这些数字包括与药物不良相互作用相关的死亡，每年可能导致多达7，000例死亡。其他报告称，6.7%的住院患者发生严重药物不良反应，病死率为0.32%。2总的来说，这些估计表明，药物不良相互作用是患者发病率和死亡率的重要因素。然而，这些统计数据并不反映在门诊和门诊环境中发生的不良药物相互作用。虽然由于数据收集和方法学问题的限制而难以计算，但药物不良相互作用似乎是一个重要但可预防的公共卫生问题。近年来，在使用美国食品和药物管理局（FDA）批准的药物治疗阿片类药物依赖的背景下发生的药物相互作用已变得明显当美沙酮（美沙酮或丁丙诺啡）用于治疗疼痛时，或当美沙酮用于治疗疼痛时，已经成为与这些疗法相关的不良事件的重要因素。这些不良事件对患者及其疾病的治疗有显著影响。
Drug interactions are a significant source of morbidity and mortality in the United States. The Institute of Medicine reported in 2000 that as many as 44,000 to 98,000 deaths are estimated to occur annually as a result of medical errors. 1 Included in these numbers are deaths related to adverse drug interactions that may contribute to up to 7,000 deaths yearly. Others have reported that 6.7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%. 2 Taken together, these estimates indicate that adverse drug interactions are an important contributor to patient morbidity and mortality. However, these statistics do not reflect adverse drug interactions that occur in out-patient and ambulatory settings. While difficult to calculate because of limitations on data collection and methodological issues, it appears that adverse drug interactions are a significant but preventable public health problem.In recent years, it has become apparent that drug interactions that occur in the context of treatment of opioid dependence with current US Food and Drug Administration (FDA) approved medications (methadone or buprenorphine), or when methadone is used in the treatment of pain, have become an important factor in adverse events associated with these therapies. These adverse events have significant impact on the patient and on the treatment of their disease.